Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.185    0.00 (0.00%)
Bid:
0.18
Ask:
0.19
Spread: 0.01 (5.556%)
Market Cap: £1.37m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Additional Listing

3 Oct 2006 07:00

Azure Holdings PLC03 October 2006 Azure Holdings plc (the "Company") First Day of Dealings on AIM Following the approval of the special resolutions at the Extraordinary GeneralMeeting ("EGM") and Class Meetings held yesterday, the Company announces theadmission, in aggregate, of 885,191,389 ordinary shares of 0.2p each ("OrdinaryShares") to trading on AIM today. At the EGM, Barry Gold resigned as a director of the Company. Anthony Moore wasappointed Non-executive Chairman; Dr Satu Vainikka was appointed ChiefExecutive; Dr Jacob Micallef was appointed Chief Operating Officer; Dr GeorgeMorris was appointed Chief Development Officer and Kevin Alexander was appointedas a Non-executive Director of the Company. Gerald Desler remains as FinanceDirector. The Company's name is expected to change to ValiRx plc effective from 4 October2006. Anthony Moore, Non-executive Chairman, ValiRx plc, commented: 'I am delighted that the reverse transaction into Azure Holdings plc hascompleted and the enlarged group is quoted on AIM. I believe that the Companyhas some exciting products and I look forward to their development andanticipate regular positive newsflow." For further information, please contact: ValiRx plcAnthony MooreDr Satu VainikkaTel: 0207 408 5400 WH Ireland LimitedDavid YoungmanTel: 0161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Jan 20241:48 pmRNSResult of GM, Issue of Equity
19th Dec 20236:11 pmRNSResult of Retail Offer, Subscription
15th Dec 20237:00 amRNSPosting of Circular, Notice of GM and Ops Review
13th Dec 20234:56 pmRNSRetail Offer
13th Dec 20234:49 pmRNSConditional Fundraise, Notice of General Meeting
5th Dec 20237:00 amRNSAgreement to License VAL401 to Ambrose Healthcare
10th Nov 20237:00 amRNSEvaluation Agreement with StingRay Bio
6th Oct 202310:45 amRNSStatement re Share Price Movement
28th Sep 20237:00 amRNSOperational Review
24th Aug 20237:00 amRNSHalf-year Report
14th Aug 20237:00 amRNSCollaborative Services Agreement
19th Jul 20237:00 amRNSInaphaea BioLabs secures first external contract
28th Jun 20232:15 pmRNSResult of AGM
20th Jun 20237:00 amRNSVirtual AGM Access
19th Jun 20237:00 amRNSInaphaea BioLabs Operational Update
16th Jun 20237:00 amRNSConclusion of Hokkaido Evaluation Agreement
14th Jun 20237:00 amRNSAsset Purchase – Imagen Therapeutics
8th Jun 20237:00 amRNSUpdate on proposed sub-license of VAL201
7th Jun 20237:00 amRNSExpanded agreement with University of Barcelona
5th Jun 20237:00 amRNSFinal Results and Notice of AGM
26th May 20237:00 amRNSNotice of Results and Investor Webinar
26th Apr 20237:00 amRNSCollaborative Services Agreement
31st Mar 20237:00 amRNSQuarterly Operational Update
1st Mar 20237:02 amRNSInvestor Webinar
1st Mar 20237:00 amRNSIncorporation of Inaphaea BioLabs Limited
24th Feb 20234:40 pmRNSSecond Price Monitoring Extn
24th Feb 20234:35 pmRNSPrice Monitoring Extension
2nd Feb 202312:45 pmRNSResult of GM, Issue of Equity
31st Jan 20237:02 amRNSOperational Update
31st Jan 20237:00 amRNSHolding(s) in Company
17th Jan 20234:36 pmRNSBroker Offer Results
17th Jan 20239:22 amRNSPosting of Circular and Notice of General Meeting
13th Jan 20237:01 amRNSLaunch of Broker Offer
13th Jan 20237:00 amRNSIssue of Equity & Proposed Broker Offer
14th Dec 20225:01 pmRNSHolding(s) in Company
7th Dec 20221:06 pmRNSHolding(s) in Company
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
6th Dec 202212:00 pmRNSShareholder Communications and Investor Webinar
6th Dec 20227:00 amRNSQuarterly Operational and Strategy Update
24th Oct 20227:00 amRNSSubsidiary Launched and IP License Signed
18th Oct 20227:00 amRNSIssue of Share Options
11th Oct 20227:00 amRNSDirector Appointment
30th Sep 20228:47 amRNSHolding(s) in Company
22nd Sep 20227:00 amRNSLive Shareholder Q&A and industry events
8th Sep 20227:00 amRNSAppointment of Interim Chief Scientific Officer
6th Sep 20227:15 amRNSProposed Appointment of Non-Executive Director
6th Sep 20227:00 amRNSIssue of Share Options
31st Aug 20227:00 amRNSHalf-year Report
17th Aug 20227:00 amRNSShareholder Communications

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.